Nihal Seden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nihal Seden has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Özgür Yiğit
Otorhinolaryngology and Head and Neck Surgery, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey
5 shared publications - Enes Yiğit
Clinic of Otorhinolaryngology, İstanbul Training and Research Hospital, İstanbul, Turkey
3 shared publications - Ismail Kaygisiz
Department of Otorhinolaryngology/Head and Neck Surgery, University of Health Sciences Istanbul Training and Research Hospital, Istanbul, Turkey
2 shared publications Abdurrahman Cagliyan
Department of Otorhinolaryngology Istanbul Education and Research Hospital Istanbul Turkey
1 shared publication- Abdurrahman Çağlıyan
University of Health Sciences Türkiye, İstanbul Training and Research Hospital, Department of Otorhinolaryngology, Division of Head and Neck Surgery, İstanbul, Türkiye
1 shared publication - Ahmet Volkan Sünter
Department of Otorhinolaryngology/Head and Neck Surgery, Istanbul Training and Research Hospital, Istanbul, Turkey
1 shared publication
Latest Publications
- 27 March 2023
- Published by Wiley in Clinical Otolaryngology
- Vol. 48 (4) , 623-629
Effect of the povidone iodine, hypertonic alkaline solution and saline nasal lavage on nasopharyngeal viral load in COVID‐19
Objective: The present study aimed to investigate the in vivo activity of nasal irrigation (NI) with saline, NI with povidone–iodine (PVP–I) 1%, NI with a mix of hypertonic alkaline and PVP–I 1% against Severe acute respiratory syndrome‐coronavirus‐2 (SARS‐CoV‐2).Design: This study was a prospective randomised clinical trial.Setting: A multicenter study involving tertiary care centres.Participants: The study included adult outpatients whose qualitative SARS‐CoV‐2 RT‐PCR tests in nasopharyngeal swabs were positive. One hundred twenty patients were divided into four equal groups. Standard COVID‐19 treatment was given to Group 1, NI containing saline was added to patients' treatment in Group 2, NI containing 1% PVP–I solution was added to patients' treatment in Group 3, and NI containing 1% PVP–I solution and the hypertonic alkaline solution was added to patients' treatment in Group 4.Main Outcome Measures: On the first day of diagnosis (Day 0), nasopharyngeal swab samples were taken, on the third and fifth days the nasopharyngeal viral load (NVL) reduction in quantitative RT‐PCR test was calculated.Results: Between the zeroth to third days and zeroth to fifth days, the NVL reduction was significant in all groups (p < .05). In paired comparisons of groups, the NVL decrease in Group 4 in the first 3 days was significantly lower than all groups (p < .05). The NVL decrease in Groups 3 and 4 in the first 5 days were significantly lower than Group 1 (p < .05).Conclusion: This study revealed that the use of NI of 1% PVP–I and the hypertonic alkaline solution mixture was more effective in reducing NVL.
- 27 March 2023
- Published by Wiley in Clinical Otolaryngology
- Vol. 48 (4) , 623-629
Effect of the povidone iodine, hypertonic alkaline solution and saline nasal lavage on nasopharyngeal viral load in COVID‐19
Objective: The present study aimed to investigate the in vivo activity of nasal irrigation (NI) with saline, NI with povidone–iodine (PVP–I) 1%, NI with a mix of hypertonic alkaline and PVP–I 1% against Severe acute respiratory syndrome‐coronavirus‐2 (SARS‐CoV‐2).Design: This study was a prospective randomised clinical trial.Setting: A multicenter study involving tertiary care centres.Participants: The study included adult outpatients whose qualitative SARS‐CoV‐2 RT‐PCR tests in nasopharyngeal swabs were positive. One hundred twenty patients were divided into four equal groups. Standard COVID‐19 treatment was given to Group 1, NI containing saline was added to patients' treatment in Group 2, NI containing 1% PVP–I solution was added to patients' treatment in Group 3, and NI containing 1% PVP–I solution and the hypertonic alkaline solution was added to patients' treatment in Group 4.Main Outcome Measures: On the first day of diagnosis (Day 0), nasopharyngeal swab samples were taken, on the third and fifth days the nasopharyngeal viral load (NVL) reduction in quantitative RT‐PCR test was calculated.Results: Between the zeroth to third days and zeroth to fifth days, the NVL reduction was significant in all groups (p < .05). In paired comparisons of groups, the NVL decrease in Group 4 in the first 3 days was significantly lower than all groups (p < .05). The NVL decrease in Groups 3 and 4 in the first 5 days were significantly lower than Group 1 (p < .05).Conclusion: This study revealed that the use of NI of 1% PVP–I and the hypertonic alkaline solution mixture was more effective in reducing NVL.
- 1 February 2023
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 24 (1) , 1-5
Short-term Postoperative Outcomes of Platelet-rich Plasma after Inferior Turbinate Radiofrequency
- 1 February 2023
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 24 (1) , 1-5
Short-term Postoperative Outcomes of Platelet-rich Plasma after Inferior Turbinate Radiofrequency
- Open Access
- 27 October 2022
- Published by Baycinar Tibbi Yayincilik in Praxis of Otorhinolaryngology
- Vol. 10 (3) , 110-114
Anosmia/hyposmia differences between severe acute respiratory syndrome coronavirus 2 variants; objective olfactory function evaluation
Objectives: This study aimed to investigate whether the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants cause more or less loss of smell than the wild type variant as a clinical finding that may guide physicians in addition to the increased mortality feature. Patients and Methods: In the prospective study, Connecticut Chemosensory Clinical Research Center (CCCRC) odor testing was performed on patients hospitalized for coronavirus disease 2019 (COVID-19) between May 2021 and December 2021, and variants of SARS-CoV-2 isolated from patients were analyzed. A total of 51 patients (30 males and 21 females; mean age 59.3±14.2 years; range, 29 to 88 years) were included in the study. Age, sex, and COVID-19 vaccine status of the patients were recorded. The patients were asked whether they had new-onset odor or taste complaints and whether they differently perceived smells they knew. Results: The delta variant was detected in 14 patients, the alpha variant was detected in 20 patients, and no variant of concern was detected in 17 patients. Odor disorders were present in 79.4% of all patients (13.73% anosmia, 15.69% severe hyposmia, 13.7% moderate hyposmia, and 37.2% mild hyposmia). There was no statistically significant difference between sex, age, smoking habits, presence of parosmia, degree of smell disorder, and Vicks definition results according to the variants (p>0.05). A statistically significant difference was found between alpha and delta variants in terms of patients' complaints of decreased smell and taste, mean olfactory threshold value, and mean olfactory score variables (p<0.05). There was no difference in terms of age and identification score. The complaints of smell and taste disorders, the mean threshold value of odor, and the mean odor score were found to be significantly lower in the delta variant than in the alpha variant. Conclusion: SARS-CoV-2 variants differ significantly in olfactory dysfunction. Future clinical and laboratory studies may show the diagnostic, clinical, and prognostic significance of olfactory nerve injury.
- 27 October 2022
- Published by Baycinar Tibbi Yayincilik in Praxis of Otorhinolaryngology
- Vol. 10 (3) , 110-114
Open AccessAnosmia/hyposmia differences between severe acute respiratory syndrome coronavirus 2 variants; objective olfactory function evaluation
Objectives: This study aimed to investigate whether the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants cause more or less loss of smell than the wild type variant as a clinical finding that may guide physicians in addition to the increased mortality feature. Patients and Methods: In the prospective study, Connecticut Chemosensory Clinical Research Center (CCCRC) odor testing was performed on patients hospitalized for coronavirus disease 2019 (COVID-19) between May 2021 and December 2021, and variants of SARS-CoV-2 isolated from patients were analyzed. A total of 51 patients (30 males and 21 females; mean age 59.3±14.2 years; range, 29 to 88 years) were included in the study. Age, sex, and COVID-19 vaccine status of the patients were recorded. The patients were asked whether they had new-onset odor or taste complaints and whether they differently perceived smells they knew. Results: The delta variant was detected in 14 patients, the alpha variant was detected in 20 patients, and no variant of concern was detected in 17 patients. Odor disorders were present in 79.4% of all patients (13.73% anosmia, 15.69% severe hyposmia, 13.7% moderate hyposmia, and 37.2% mild hyposmia). There was no statistically significant difference between sex, age, smoking habits, presence of parosmia, degree of smell disorder, and Vicks definition results according to the variants (p>0.05). A statistically significant difference was found between alpha and delta variants in terms of patients' complaints of decreased smell and taste, mean olfactory threshold value, and mean olfactory score variables (p<0.05). There was no difference in terms of age and identification score. The complaints of smell and taste disorders, the mean threshold value of odor, and the mean odor score were found to be significantly lower in the delta variant than in the alpha variant. Conclusion: SARS-CoV-2 variants differ significantly in olfactory dysfunction. Future clinical and laboratory studies may show the diagnostic, clinical, and prognostic significance of olfactory nerve injury.
- Open Access
- 22 September 2022
- Published by Kare Publishing in SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital
- Vol. 56 (3) , 343-352
Validation and clinical application of the Turkish version of the RhinoQOL questionnaire in the setting of chronic rhinosinusitis with nasal polyp patients
The Medical Bulletin of Sisli Etfal Hospital
- 22 September 2022
- Published by Kare Publishing in SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital
- Vol. 56 (3) , 343-352
Open AccessValidation and clinical application of the Turkish version of the RhinoQOL questionnaire in the setting of chronic rhinosinusitis with nasal polyp patients
The Medical Bulletin of Sisli Etfal Hospital
- 1 August 2022
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 23 (3) , 170-173
Tumor/Nodule Size Ratio: A Possible Reason for False-Negative Thyroid Cytology
- 1 August 2022
- Published by Galenos Yayinevi in Istanbul Medical Journal
- Vol. 23 (3) , 170-173
Tumor/Nodule Size Ratio: A Possible Reason for False-Negative Thyroid Cytology
- Open Access
- 8 December 2021
- Published by IntechOpen
Loss of Smell and Taste as Clinical Onset of COVID-19
Initially, symptoms of COVID-19 associated with Ear-Nose-Throat were thought to be flulike symptoms in the foreground. Such as fever, chills, cough, dyspnoea, myalgia, headache, sore throat. Olfactory and gustatory dysfunction was not a noticeable symptom at first. As the number of cases has risen worldwide, sudden onset hyposmia/anosmia has received increasing attention as a symptom of COVID-19. The reported incidence of anosmia varies internationally: as low as 30% in South Korea, and as high as 88% in Europe. The loss of smell that occurs in COVID-19 infection its general character is sudden onset anosmia. There is currently no specific treatment for COVID-19 related anosmia. Olfactory dysfunction can heal spontaneously. However, not a small number of patients may have permanent impairment.
- 8 December 2021
- Published by IntechOpen
Open AccessLoss of Smell and Taste as Clinical Onset of COVID-19
Initially, symptoms of COVID-19 associated with Ear-Nose-Throat were thought to be flulike symptoms in the foreground. Such as fever, chills, cough, dyspnoea, myalgia, headache, sore throat. Olfactory and gustatory dysfunction was not a noticeable symptom at first. As the number of cases has risen worldwide, sudden onset hyposmia/anosmia has received increasing attention as a symptom of COVID-19. The reported incidence of anosmia varies internationally: as low as 30% in South Korea, and as high as 88% in Europe. The loss of smell that occurs in COVID-19 infection its general character is sudden onset anosmia. There is currently no specific treatment for COVID-19 related anosmia. Olfactory dysfunction can heal spontaneously. However, not a small number of patients may have permanent impairment.
- 24 November 2021
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 46 (4) , 1760-1770
The Impact of Isotretinoin Therapy on the Nasal Skin Thickness and Elasticity: An Ultrasonography and Elastography Based Assessment in Relation to Dose and Duration of Therapy
Background This study aimed to evaluate the impact of isotretinoin therapy on the nasal skin thickness and elasticity with regard to implications for rhinoplasty Methods A total of 40 acne vulgaris patients (mean±SD age: 20.9 ± 3.0 years, 65.0% were females) initiating oral isotretinoin treatment (0.25 mg/kg/day, n = 16 or 0.5 mg/kg/day, n = 24) were included in this prospective 4-month isotretinoin follow-up study. Ultrasonography assessments regarding nasal skin thickness (dermis and soft tissue) and elastography were repeated at second and fourth months of treatment. Results No significant difference was noted between isotretinoin dose groups in terms of second month and fourth month nasal skin thickness (dermis and soft tissue) values measured at any region. Each dose revealed significant decrease in dermis and soft tissue thickness from baseline at any region (p ranged < 0.001 to < 0.001), while only fourth month values at nasal tip and second month values at rhinion for dermis and only fourth month values at rhinion and glabella for subcutaneous tissue significantly differed from baseline (p < 0.01 for each) in the 0.25 mg and 0.50 mg dose groups, respectively. Elastography values at fourth month of isotretinoin treatment were significantly higher than pre-treatment and second month values in both 0.25 mg (90.4 ± 20.6 vs. 59.5 ± 21.8 and 76.4 ± 22.9, p < 0.01 for each) and 0.5 mg (86.7 ± 20.6 vs. 61.8 ± 23.2 and 76.9±24, p < 0.01 for each) dose groups. Conclusions In conclusion, our findings revealed the association of isotretinoin treatment with a significant decrease in dermis and subcutaneous soft tissue thickness measured at each anatomical landmark, regardless of the treatment dose. Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266
- 24 November 2021
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 46 (4) , 1760-1770
The Impact of Isotretinoin Therapy on the Nasal Skin Thickness and Elasticity: An Ultrasonography and Elastography Based Assessment in Relation to Dose and Duration of Therapy
Background This study aimed to evaluate the impact of isotretinoin therapy on the nasal skin thickness and elasticity with regard to implications for rhinoplasty Methods A total of 40 acne vulgaris patients (mean±SD age: 20.9 ± 3.0 years, 65.0% were females) initiating oral isotretinoin treatment (0.25 mg/kg/day, n = 16 or 0.5 mg/kg/day, n = 24) were included in this prospective 4-month isotretinoin follow-up study. Ultrasonography assessments regarding nasal skin thickness (dermis and soft tissue) and elastography were repeated at second and fourth months of treatment. Results No significant difference was noted between isotretinoin dose groups in terms of second month and fourth month nasal skin thickness (dermis and soft tissue) values measured at any region. Each dose revealed significant decrease in dermis and soft tissue thickness from baseline at any region (p ranged < 0.001 to < 0.001), while only fourth month values at nasal tip and second month values at rhinion for dermis and only fourth month values at rhinion and glabella for subcutaneous tissue significantly differed from baseline (p < 0.01 for each) in the 0.25 mg and 0.50 mg dose groups, respectively. Elastography values at fourth month of isotretinoin treatment were significantly higher than pre-treatment and second month values in both 0.25 mg (90.4 ± 20.6 vs. 59.5 ± 21.8 and 76.4 ± 22.9, p < 0.01 for each) and 0.5 mg (86.7 ± 20.6 vs. 61.8 ± 23.2 and 76.9±24, p < 0.01 for each) dose groups. Conclusions In conclusion, our findings revealed the association of isotretinoin treatment with a significant decrease in dermis and subcutaneous soft tissue thickness measured at each anatomical landmark, regardless of the treatment dose. Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266
- 27 October 2021
- Published by Cambridge University Press (CUP) in The Journal of Laryngology & Otology
- Vol. 136 (1) , 55-59
Does turbinate reduction combined with septoplasty have better outcomes than septoplasty alone? A randomised, controlled study
Objective: This study investigated whether inferior turbinate reduction combined with septoplasty improves patients’ outcomes, as assessed by objective and subjective methods.Methods: A single-centre, parallel-group, randomised, open-label trial was conducted at a tertiary hospital ENT clinic. Patients who underwent septoplasty were divided into two groups: group A underwent septoplasty with radiofrequency ablation; group B underwent only septoplasty. All patients were assessed before and three months after surgery using acoustic rhinometry and peak nasal inspiratory flow measurements, as well as Nasal Obstruction Symptom Evaluation scale and Sino-Nasal Outcome Test-22 scores.Results: Seventy-four patients completed the study (36 in group A and 38 in group B). The patients in both groups showed significant improvements in acoustic rhinometry and peak nasal inspiratory flow measurements and in Nasal Obstruction Symptom Evaluation scale and Sino-Nasal Outcome Test-22 scores after the surgery (p < 0.05). However, the differences between the groups were not significant (p > 0.05).Conclusion: Inferior turbinate ablation combined with septoplasty does not provide any more benefit to the objective and subjective outcomes of patients than septoplasty alone.
- 27 October 2021
- Published by Cambridge University Press (CUP) in The Journal of Laryngology & Otology
- Vol. 136 (1) , 55-59
Does turbinate reduction combined with septoplasty have better outcomes than septoplasty alone? A randomised, controlled study
Objective: This study investigated whether inferior turbinate reduction combined with septoplasty improves patients’ outcomes, as assessed by objective and subjective methods.Methods: A single-centre, parallel-group, randomised, open-label trial was conducted at a tertiary hospital ENT clinic. Patients who underwent septoplasty were divided into two groups: group A underwent septoplasty with radiofrequency ablation; group B underwent only septoplasty. All patients were assessed before and three months after surgery using acoustic rhinometry and peak nasal inspiratory flow measurements, as well as Nasal Obstruction Symptom Evaluation scale and Sino-Nasal Outcome Test-22 scores.Results: Seventy-four patients completed the study (36 in group A and 38 in group B). The patients in both groups showed significant improvements in acoustic rhinometry and peak nasal inspiratory flow measurements and in Nasal Obstruction Symptom Evaluation scale and Sino-Nasal Outcome Test-22 scores after the surgery (p < 0.05). However, the differences between the groups were not significant (p > 0.05).Conclusion: Inferior turbinate ablation combined with septoplasty does not provide any more benefit to the objective and subjective outcomes of patients than septoplasty alone.
- 1 January 2021
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 42 (1) , 102761
Objective evaluation of odor loss in COVID-19 and other suspected cases
- 1 January 2021
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 42 (1) , 102761
Objective evaluation of odor loss in COVID-19 and other suspected cases